Two Sigma Advisers LP Acquires 23,700 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Two Sigma Advisers LP raised its position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 254.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,000 shares of the company’s stock after buying an additional 23,700 shares during the quarter. Two Sigma Advisers LP’s holdings in Dr. Reddy’s Laboratories were worth $521,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. AIA Group Ltd grew its holdings in Dr. Reddy’s Laboratories by 441.7% during the 4th quarter. AIA Group Ltd now owns 145,150 shares of the company’s stock valued at $2,292,000 after buying an additional 118,357 shares in the last quarter. Vanguard Group Inc. grew its holdings in Dr. Reddy’s Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company’s stock valued at $77,311,000 after buying an additional 3,911,404 shares in the last quarter. Van ECK Associates Corp grew its holdings in Dr. Reddy’s Laboratories by 609.4% during the 4th quarter. Van ECK Associates Corp now owns 5,838 shares of the company’s stock valued at $92,000 after buying an additional 5,015 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Dr. Reddy’s Laboratories by 400.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 534,304 shares of the company’s stock valued at $8,373,000 after buying an additional 427,573 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new position in Dr. Reddy’s Laboratories during the 4th quarter valued at approximately $543,000. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 8th.

Dr. Reddy’s Laboratories Price Performance

Shares of Dr. Reddy’s Laboratories stock opened at $14.66 on Wednesday. The stock has a market cap of $12.24 billion, a price-to-earnings ratio of 23.34 and a beta of 0.33. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock has a 50 day moving average price of $13.74 and a 200-day moving average price of $14.01. Dr. Reddy’s Laboratories Limited has a one year low of $12.26 and a one year high of $16.89.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Friday, May 9th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.02. The firm had revenue of $996.17 million during the quarter, compared to analysts’ expectations of $83.70 billion. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Equities analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.